Radio-chemotherapy with CDDP is the standard for H&N squamous cell cancer. CDDP 100 mg/m /q3 is the standard; alternative schedules are used to reduce toxicity, mostly 40 mg/m /q1. Patients were treated from 1/2010 to 1/2017 in two Radiation Oncology Centres. Propensity score analysis (PS) was retrospectively used to compare these two schedules. Patients analyzed were 166. Most (114/166) had 1w-CDDP while 52 had 3w-CDDP. In the 3w-CDDP group, patients were younger, with better performance status, smaller disease extent and a more common nodal involvement than in the 1w-CDDP. Acute toxicity was similar in the groups. Treatment compliance was lower in the w-CCDP. Overall survival before PS was better for female, for oropharyngeal disease and for 3w-CDDP group. After PS, survival was not related to the CDDP schedule. 3w-CDDP remains the standard for fit patients, weekly schedule could be safely used in selected patients.